Alcuronium 0.16 mg kg"' was used to provide neuromuscular blockade in patients with chronic renal failure undergoing renal transplantation. Byl»mtinn was found to be adequate for intubation and surgery. There were minimal alterations to cardiovascular variables. The dose required was small, and complete reversal occurred with neostigmine. Although the number of patients is small, the drug may be of value as an alternative to tubocurarine or pancuronium in such patients.
Many instances of prolonged neuromuscular blockade requiring continued mechanical ventilation have been reported following the use of nondepolarizing myoneural blocking drugs in patients with chronic renal failure (Riordan and Gilbertson, 1971; Abraham and Hornbein, 1975; Rouse, Gaily and Bevan, 1977) . Impaired renal function, decreased plasma clearance and prolonged duration of action have all been suggested as possible causes of prolonged neuromuscular blockade (McLeod, Watson and Rawlins, 1976; Miller and Cullen, 1976; Somogy, Shanks and Triggs, 1977) .
Alcuronium (diallyl nor-toxiferine), a synthetic non-depolarizing drug, was introduced into clinical practice by Hugin and Kissling (1961) . However, it does not appear to have been used in patients undergoing renal transplantation, or in patients with chronic renal failure. Specificity of action, minimal cardiovascular effects (Canak, 1965; Tammisto and Welling, 1969; Kennedy and Kelman, 1970) excellent relaxation and easy reversibility (Foldes et al., 1963) have prompted us to use the drug in patients with end-stage renal failure undergoing transplantation and its use forms the basis of this report.
PATIENTS AND METHODS
Ten anuric patients (eight male) with chronic renal failure, who were to undergo renal transplantation from living related donors, were studied. The youngest was 17yr and the oldest 40 yr, and their average weight was 49.9 ± 5.5 kg. All patients were hypertensive with arterial pressures ranging from 160/100 mm Hg to 240/130 mm Hg, and were receiving antihypertensive therapy in the form of methyldopa 700-lOOOmgday" 1 , frusemide 40-80mg and propranolol 120-360 mg. Mean duration of disease was 1.25yr±6.72. Serum protein concentrations were generally low and the albumin:globulin ratio was altered in all but one patient. Blood urea concentration was greater than 15 mmol litre"' in all patients, the greatest value being 46.8 mmol litre"
1 . Serum creatinine concentrations were greater than 660 junol litre" 1 in all patients. Plasma electrolyte concentrations obtained before induction of anaesthesia were within normal limits. The total number of haemodialyses varied between 16 and 22 and each patient was dialysed within the 48 h immediately preceding surgery. Investigations carried out before the induction of anaesthesia are shown in table I.
Each patient was premedicated with diazepam 10 mg at night and diazepam 10 mg orally 2 h before operation. After preoxygenation, anaesthesia was induced with thiopentone 5mgkg"'. Alcuronium 0.16 mg kg" 1 was given and the lungs ventilated with 50% nitrous oxide in oxygen and 0.5-1% halothane. Once apnoea had occurred, intubation of the trachea was attempted. Conditions for intubation were graded according to Lund and Stovner (1962) . Anaesthesia was maintained with nitrous oxide and 0.5-1% halothane in oxygen. Ventilation was controlled. Alcuronium 1-2 mg was given as and when required. For analgesia, morphine in doses of 0.1 mgkg" 1 was given just before skin incision. At the end of surgery the residual effect of the neuromuscular blocking drug was antagonized with neostigmine 2.5 mg (plus atropine 1.2 mg) when some respiratory effort was noticed. Duration of
apnoea, arterial pressure, heart rate, ECG, CVP and adequacy of reversal, were monitored.
RESULTS
Adequate neuromuscular blockade as judged by the relaxation of the jaw and vocal cords and the absence of straining, was achieved within a mean time of 106 (± 9.3) s. Endotracheal intubation was possible in all patients; although the conditions could not be graded as excellent, they were acceptable (table II) .
A rterial pressure
Alcuronium caused a 17% decrease in systolic arterial pressure and a 19% decrease in mean arterial pressure within 2min of administration (P< 0.001). However, there was a small increase (average of 7mmHg systolic (lOmmHg mean)) from this value during endotracheal intubation. The decrease was maximum after 30 min ( fig. 1 ).
Heart rate, ECG and CVP
There was an insignificant increase in heart rate which increased further during endotracheal intubation ( fig. 2) . No arrhythmias were noted during the period of study. Central venous pressure was unchanged.
Duration and dose
The average duration of action of the first dose was 37± 12.5 min, based on the interval between the first and second doses. The criteria determining the need for a second dose were based on clinical indices such as bag pressure, and an assessment of neuromuscular blockade using a peripheral nerve stimulator. Average total dose required for the whole duration of surgery was 15.6 mg (±2.27), that 
Reversal
The mean reversal times as judged by the return of adequate respiration and the opening of the eyes were 61.5 and 89.5 s, respectively. Complete reversal of relaxation occurred in all patients. At the end of surgery urinary output was adequate in seven of the 10 patients. In three patients no output of urine could be established and these patients were put on an antirejection regimen from the 2nd day.
DISCUSSION
Inadequate reversal of non-depolarizing myoneural blockers is a possibility in patients with chronic renal failure, and was first reported by Fairley (1950) following the use of gallamine. Tubocurarine and pancuronium have resulted in prolonged curarization (Abraham and Hombein, 1975; Miller and Cullen, 1976; d'Hollander, Camu and Sanders, 1978) such that pancuronium, once considered an ideal drug, is no longer the drug of choice for patients undergoing renal transplantation (McLeod, Watson and Rawlins, 1975 ). It appears that alcuronium has not been used in patients undergoing renal transplantation. Certainly some authors have cautioned against its use in renal failure (Atkinson, 1977) . Havill and colleagues (1978) have even suggested that its use in such patients "is probably contra-indicated", but no specific reasons have been given. In the present investigation, intubating conditions were found to be satisfactory. Some degree of tachycardia was seen during intubation, but this was not significant statistically and may have been the result of intubation under light anaesthesia.
The results suggest that the principal cardiovascular effect of alcuronium may be a decrease in arterial pressure, but the effect is minimal. This observation is in keeping with the work of Tammisto and Welling (1969) , although Kennedy and Kelman (1970) did observe an 18-20% decrease in arterial pressure. Hunter (1964) and Baraka (1967) reported greater decreases in arterial pressure, but the initial dose of the drug used in their series was larger. The drug is known to be bound to albumin and Stovner, Theodoraan and Bjleke (1971) demonstrated a positive correlation with albumin concentration. Patients with chronic renal failure may have low albumin concentrations, and the albumin:globulin ratio may be altered. Nine of 10 patients in the present series had alteration in albumin:globulin ratio, and this may have been responsible for the smaller dose requirement, and hence the less marked cardiovascular effects.
Halothane 1 -2% is known to decrease the requirement for tubocurarine (Katz and Gisson, 1967) . Whether the requirement for alcuronium is also decreased is not documented in literature. In the present series, halothane 0.5-1% was given intermittently and, therefore, it is unlikely that this was responsible for smaller dose requirements. Reversal was adequate in all patients. Alcuronium is known to be excreted through the kidneys although, since it is structurally similar to tubocurarine, a longer alternative route of excretion through the biliary system is possible in chronic renal failure.
